Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Michigan
Clinical trial register · United States · industry-sponsored

Clinical Trials in Michigan, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 109 Florida 91 Colorado 71 Georgia 67 Illinois 56
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca53 Janssen Research & Development, LLC41 Eli Lilly and Company40 AbbVie35 Merck Sharp & Dohme LLC34 Clear sponsor filter
State
California109 Florida91 Colorado71 Georgia67 Illinois56
All 42 states
Target enrolment
to

Trials with a site in Michigan

41 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
NCT07746713Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
100
Florida, Michigan, Utah
2026-08-05
Recruiting
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
NCT07309445Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Observational
150
Alabama, Arkansas, California, Colorado, Florida, Illinois, Indiana, Michigan
2026-06-12
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-22
Recruiting
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
NCT07572006Hematologic Neoplasms
Janssen Research & Development, LLC
Phase 1
360
Indiana, Michigan, New Jersey, New York, Tennessee, Texas
2026-05-13
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
California, Colorado, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey
2026-03-05
Recruiting
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
NCT07615426Schizophrenia
Janssen Research & Development, LLC
Phase 1
64
California, Georgia, Illinois, Michigan, New York, Texas
2026-03-02
Active, closed
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860Dermatitis, Atopic
Janssen Research & Development, LLC
Phase 2
189
California, Florida, Illinois, Indiana, Michigan, North Dakota, Oregon, Pennsylvania
2026-01-20
Recruiting
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
NCT06800313Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2
190
Colorado, Connecticut, Florida, Louisiana, Massachusetts, Michigan, Nebraska, New York
2025-02-06
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Michigan
2024-12-04
Recruiting
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms
DrugsFolfiri·Folfox·Bevacizumab
Janssen Research & Development, LLC
Phase 1
260
Arizona, Colorado, Florida, Indiana, Michigan, Washington
2024-10-15
Active, closed
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NCT06550895Multiple Myeloma
DrugsCilta-cel·Talquetamab
Janssen Research & Development, LLC
Phase 2
11
Iowa, Kentucky, Michigan, New York, Pennsylvania
2024-09-16
Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Paraplatin·Taxol·Keytruda
Janssen Research & Development, LLC
Phase 1/2
287
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Missouri
2024-04-22
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
DrugsTAR-200·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
272
Arkansas, California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan
2024-04-09
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
DrugsMomelotinib·Ruxolitinib
Janssen Research & Development, LLC
Phase 1
300
California, Colorado, Florida, Georgia, Michigan, New Jersey, New York, North Carolina
2023-12-20
Recruiting
A Study of JNJ-87890387 for Advanced Solid Tumors
NCT06178614Neoplasms, Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1
200
Michigan, Tennessee
2023-12-14
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
DrugsJNJ-101556143·Lutetium Lu-177 vipivotide tetraxetan·Pasritamig·Cabazitaxel
Janssen Research & Development, LLC
Phase 1
300
Florida, Michigan, Missouri, New York, Pennsylvania
2023-04-26
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
213
Florida, Georgia, Michigan, Missouri, New York, Texas
2022-12-15
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
201
Colorado, Florida, Georgia, Kansas, Maryland, Massachusetts, Michigan, Missouri
2022-09-23
Active, closed
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510Colitis, Ulcerative
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3
Janssen Research & Development, LLC
Phase 3
418
Arizona, California, Colorado, Florida, Georgia, Kansas, Michigan, New York
2022-09-13
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 3
418
California, Colorado, Florida, Kansas, Michigan, New Jersey, New York, Oregon
2022-08-05
Recruiting
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595Advanced or Metastatic Colorectal Cancer
DrugsAmivantamab·Fluorouracil·Leucovorin·Irinotecan
Janssen Research & Development, LLC
Phase 1/2
225
Alabama, California, District of Columbia, Florida, Maryland, Michigan, Mississippi, New York
2022-07-29
Recruiting
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
NCT05265273Myasthenia Gravis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
12
Arizona, California, Colorado, Florida, Kansas, Michigan, Pennsylvania
2022-07-20
Active, closed
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
NCT05379634Myositis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2
36
Arizona, California, Florida, Georgia, Kansas, Maryland, Massachusetts, Michigan
2022-07-05
Active, closed
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973Amyloidosis
DrugsBortezomib·Daratumumab·Dexamethasone·Cyclophosphamide
Janssen Research & Development, LLC
Phase 2
151
California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York, North Carolina
2022-03-01
Active, closed
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169Multiple Myeloma
DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab
Janssen Research & Development, LLC
Phase 3
587
Alabama, California, Connecticut, Georgia, Massachusetts, Michigan, Ohio, Pennsylvania
2021-10-14
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 4
411
Arizona, Arkansas, California, Connecticut, Florida, Illinois, Maryland, Michigan
2021-08-30
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine
Janssen Research & Development, LLC
Phase 3
743
California, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts, Michigan
2021-08-19
Active, closed
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098Arthritis, Psoriatic
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
1,054
Alabama, Arizona, California, Florida, Maryland, Michigan, Missouri, Montana
2021-06-17
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Acute Leukemia
DrugBleximenib
Janssen Research & Development, LLC
Phase 1/2
420
California, Illinois, Indiana, Kentucky, Massachusetts, Michigan, New Mexico, New York
2021-05-19
Active, closed
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
NCT04662580Metastatic Prostate Cancer
DrugsARX517·Apalutamide·Abiraterone acetate·Prednisone
Janssen Research & Development, LLC
Phase 1
183
California, Georgia, Indiana, Michigan, Missouri, Nebraska, New York, Ohio
2021-05-03
Recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552Hematological Malignancies
DrugTalquetamab
Janssen Research & Development, LLC
Phase 2
510
Alabama, Arkansas, California, Florida, Georgia, Illinois, Kentucky, Michigan
2021-02-01
Active, closed
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623Urinary Bladder Neoplasms
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 2
220
Arizona, California, Colorado, Illinois, Indiana, Kansas, Michigan, New York
2020-12-18
Active, closed
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862Urinary Bladder Neoplasms
DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin
Janssen Research & Development, LLC
Phase 3
518
California, Colorado, Florida, Georgia, Illinois, Michigan, Nebraska, New Jersey
2020-12-07
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
DrugsAmivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
308
California, District of Columbia, Florida, Georgia, Michigan, Missouri, New Jersey, New York
2020-10-13
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Osimertinib
Janssen Research & Development, LLC
Phase 3
1,074
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2020-09-30
Active, closed
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098Hematological Malignancies
DrugTeclistamab
Janssen Research & Development, LLC
Phase 2
194
Alabama, California, Georgia, Michigan, New York, North Carolina, Pennsylvania
2020-09-17
Active, closed
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04077463Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
701
California, Florida, Massachusetts, Michigan, Missouri, New York, Oregon, Pennsylvania
2019-09-04
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
118
California, Colorado, Florida, Illinois, Kansas, Louisiana, Michigan, Missouri
2019-08-15
Active, closed
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350Prostatic Neoplasms, Castration-Resistant
DrugsCetrelimab·Abiraterone acetate·Niraparib·Prednisone
Janssen Research & Development, LLC
Phase 2
136
Arizona, Colorado, Florida, Indiana, Maryland, Michigan, New York, Pennsylvania
2018-03-02
Active, closed
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
NCT02609776Non-Small-Cell Lung Cancer
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
751
California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2016-05-24
Rows per page Showing 1–41 of 41
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/michigan

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 41 of those studies with a site in Michigan that also match the filters currently applied.

How many clinical trials are recruiting in Michigan?

18 of the 41 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 23 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Michigan), 41 studies
PhaseStudiesRecruitingShare
Phase 314334.1%
Phase 110724.4%
Phase 28119.5%
Phase 1/2449.8%
Phase 2/3327.3%
Observational112.4%
Phase 4102.4%

Most active sponsors

Lead sponsors with the most studies (Michigan)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC4118
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.